海藻酸钙/聚精氨酸微胶囊的制备及其生物相容性

以海藻酸盐、 聚精氨酸为壁材， 采用高压静电法制备了球形度好、 表面光洁、 粒径均匀的新型药物载体——海藻酸钙/聚精氨酸微胶囊。参照医疗器械生物学评价标准， 对其生物相容性进行了研究。细胞毒性试验结果显示， 当海藻酸钙/聚精氨酸微胶囊的含量为0.1、 0.5、 1.0 mg/mL时， 微胶囊对L929细胞生长无明显抑制作用， 海藻酸钙/聚精氨酸微胶囊浸提产物在10.0 mg/mL时仍无细胞毒性作用。海藻酸钙/聚精氨酸微胶囊不引起急性全身毒性反应， 不引起溶血反应。通过本组试验可见， 采用高压静电法制备的药物载体——海藻酸钙/聚精氨酸微胶囊具有较好的生物相容性， 具有开发和应用价值。

Preparation and biocompatibility of alginate/poly(L-arginine)microcapsules

A novel drug carrier based on alginate and poly-L-arginine was fabricated. The alginate/poly(L-arginine) microcapsules with good sphericity,  smooth surface and well roportioned particle size were prepared by the high voltage electrostatic method. According to the standard for the biological evaluation of medical devices,  the biocompatibility of alginate/poly(L-arginine) microcapsules was studied. The cytotoxicity studies show that the alginate/poly(L-arginine) microcapsules have no significant growth inhibition effect on L929 cells when they were used at 0.1,  0.5,  1.0 mg/mL. The extract productions of the alginate/poly(L-arginine) microcapsules do not show cytotoxic effect even at 10.0 mg/mL. The alginate/poly(L-arginine) microcapsules have no acute systemic toxicity and no hemolytic reaction. All results indicate that the alginate/poly(L-arginine) microcapsules,  prepared by the high voltage electrostatic method,  have acceptable biocompatibility and might be an appropriate candidate for macromolecule drug delivery,  and it is worthy of a further research.